{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002355","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.584977+00:00","generated_at":"2026-06-17T01:06:20.797099+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst secures $450M Pharmakon credit facility; draws $300M to refinance debt, extend maturity to 2028","bullets":["$300M drawn at closing; remaining $150M available on option through Sept 2024.","Net proceeds ~$26M after repaying $241.8M existing Athyrium facility and fees.","Interest: 3-month SOFR + 7.00% (1.75% floor); option to pay up to 50% interest in-kind for first six quarters (margin +0.25%).","No financial covenants, no scheduled amortization; all principal due April 2028.","Extends repayment bullet from 2025 to 2028; CFO says reduces dependence on capital markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002355","json":"https://secwatch.observer/filing/0001171843-23-002355.json","markdown":"https://secwatch.observer/filing/0001171843-23-002355.md","text":"https://secwatch.observer/filing/0001171843-23-002355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002355/0001171843-23-002355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002355/f8k_041823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:06:20.797099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37a8f05b11af2cac85b7f8edf533b196d53de0c1","claim":"BIOCRYST PHARMACEUTICALS INC incurred credit facility of $450 million Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership at three-month SOFR rate, which shall be no less than 1.75% (“SOFR”), plus 7.00%, p maturing April 17, 2028.","evidence_excerpt":"On April 17, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) entered into a $450 million Loan Agreement by and among the Company, as borrower; the guarantors from time to time party thereto; BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder; and BioPharma Credit PLC, as collateral agent for the lenders (the “Credit Agreement”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002355/0001171843-23-002355-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$450 million Loan Agreement"},{"label":"Counterparty","value":"BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership"},{"label":"Rate","value":"three-month SOFR rate, which shall be no less than 1.75% (“SOFR”), plus 7.00%, p"},{"label":"Maturity","value":"April 17, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b9e1d8578b937767dcddbda7034ae3edf4776dbf","claim":"BIOCRYST PHARMACEUTICALS INC entered into Credit Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders; BioPharma Credit PLC, as collateral agent valued at $450 million (effective 2023-04-17).","evidence_excerpt":"On April 17, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) entered into a $450 million Loan Agreement by and among the Company, as borrower; the guarantors from time to time party thereto; BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder; and BioPharma Credit PLC, as collateral agent for the lenders (the “Credit Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323002355/0001171843-23-002355-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders; BioPharma Credit PLC, as collateral agent"},{"label":"Value","value":"$450 million"},{"label":"Effective","value":"2023-04-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}